Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease

Experimental Neurology

Volumn 239, Issue 1, 2013, Pages 192-201

  Sung, You Me ^a   Lee, Taehee ^a   Yoon, Hyejin ^c   DiBattista, Amanda Marie ^a   Song, Jung Min ^a   Sohn, Yoojin ^a   Moffat, Emily Isabella ^a   Turner, R Scott ^a   Jung, Mira ^a   Kim, Jungsu ^b   Hoe, Hyang Sook ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Seoul National University   (South Korea)

Author keywords

A ; AD; Alzheimer's disease; Amyloid precursor protein; Amyloid ; APP; Epigenetics; HDACI; Histone deacetylase inhibitors

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; GAMMA SECRETASE; GELATINASE A; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIDE BASED CLASS 1 AND 2 HISTONE DEACETYLASE INHIBITOR; MERCAPTOACETAMIDE BASED CLASS 2 HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; BRAIN NERVE CELL; COGNITION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNOBLOTTING; IN VITRO STUDY; LEARNING DISORDER; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACETAMIDES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEARNING; MAZE LEARNING; MEMORY; MICE; MICE, TRANSGENIC; MICROINJECTIONS; NEURONS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; TAU PROTEINS; THIOGLYCOLATES; TRANSFECTION;

EID: 84868549261     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.10.005     Document Type: Article

References (28)

1. Cha J.H., Farrell L.A., Ahmed S.F., Frey A., Hsiao-Ashe K.K., Young A.B., Penney J.B., Locascio J.J., Hyman B.T., Irizarry M.C. Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein. Neurobiol. Dis. 2001, 8:90-102.
2. De Strooper B., Vassar R., Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:99-107.
3. Fischer A., Sananbenesi F., Mungenast A., Tsai L.H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 2010, 31:605-617.
4. Fisette J.F., Montagna D.R., Mihailescu M.R., Wolfe M.S. A G-rich element forms a G-quadruplex and regulates bace1 mRNA alternative splicing. J. Neurochem. 2012, 121(5):763-773.
5. Golde T.E., Petrucelli L., Lewis J. Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp. Neurol. 2010, 223:252-266.
6. Govindarajan N., Agis-Balboa R.C., Walter J., Sananbenesi F., Fischer A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J. Alzheimers Dis. 2011, 26:187-197.
7. Green K.N., Steffan J.S., Martinez-Coria H., Sun X., Schreiber S.S., Thompson L.M., LaFerla F.M. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J. Neurosci. 2008, 28:11500-11510.
8. Hempen B., Brion J.P. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 1996, 55:964-972.
9. Hoe H.S., Fu Z., Makarova A., Lee J.Y., Lu C., Feng L., Pajoohesh-Ganji A., Matsuoka Y., Hyman B.T., Ehlers M.D., Vicini S., Pak D.T., Rebeck G.W. The effects of amyloid precursor protein on postsynaptic composition and activity. J. Biol. Chem. 2009, 284:8495-8506.
10. Iqbal K., Grundke-Iqbal I. Pharmacological approaches of neurofibrillary degeneration. Curr. Alzheimer Res. 2005, 2:335-341.
11. Kazantsev A.G., Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 2008, 7:854-868.
12. Kilgore M., Miller C.A., Fass D.M., Hennig K.M., Haggarty S.J., Sweatt J.D., Rumbaugh G. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010, 35:870-880.
13. Konsoula R., Jung M. In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors. Int. J. Pharm. 2008, 361:19-25.
14. Konsoula Z., Cao H., Velena A., Jung M. Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors. Mol. Cancer Ther. 2009, 8:2844-2851.
15. Konsoula Z., Cao H., Velena A., Jung M. Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity. Int. J. Radiat. Oncol. Biol. Phys. 2011, 79:1541-1548.
16. Kozikowski A.P., Chen Y., Subhasish T., Lewin N.E., Blumberg P.M., Zhong Z., D'Annibale M.A., Wang W.L., Shen Y., Langley B. Searching for disease modifiers-PKC activation and HDAC inhibition - a dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress. ChemMedChem 2009, 4:1095-1105.
17. Krecic A.M., Swanson M.S. hnRNP complexes: composition, structure, and function. Curr. Opin. Cell Biol. 1999, 11:363-371.
18. Lockett G.A., Wilkes F., Maleszka R. Brain plasticity, memory and neurological disorders: an epigenetic perspective. Neuroreport 2010, 21:909-913.
19. Marks P.A., Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs 2005, 14:1497-1511.
20. Minami S.S., Clifford T.G., Hoe H.S., Matsuoka Y., Rebeck G.W. Fyn knock-down increases Abeta, decreases phospho-tau, and worsens spatial learning in 3xTg-AD mice. Neurobiol. Aging 2011, 33(4):825.e15-825.e24.
21. Nishitomi K., Sakaguchi G., Horikoshi Y., Gray A.J., Maeda M., Hirata-Fukae C., Becker A.G., Hosono M., Sakaguchi I., Minami S.S., Nakajima Y., Li H.F., Takeyama C., Kihara T., Ota A., Wong P.C., Aisen P.S., Kato A., Kinoshita N., Matsuoka Y. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J. Neurochem. 2006, 99(6):1555-1563.
22. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
23. Oddo S., Caccamo A., Tran L., Lambert M.P., Glabe C.G., Klein W.L., LaFerla F.M. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J. Biol. Chem. 2006, 281:1599-1604.
24. Qing H., He G., Ly P.T., Fox C.J., Staufenbiel M., Cai F., Zhang Z., Wei S., Sun X., Chen C.H., Zhou W., Wang K., Song W. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J. Exp. Med. 2008, 205:2781-2789.
25. Ricobaraza A., Cuadrado-Tejedor M., Marco S., Perez-Otano I., Garcia-Osta A. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 2010, 22(5):1040-1050.
26. Ricobaraza A., Cuadrado-Tejedor M., Garcia-Osta A. Long-term phenylbutyrate administration prevents memory deficits in Tg2576 mice by decreasing Abeta. Front. Biosci. (Elite Ed.) 2011, 3:1375-1384.
27. Robakis N.K. An Alzheimer's disease hypothesis based on transcriptional dysregulation. Amyloid 2003, 10:80-85.
28. Yacoubian T.A., Cantuti-Castelvetri I., Bouzou B., Asteris G., McLean P.J., Hyman B.T., Standaert D.G. Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiol. Dis. 2008, 29:515-528.